(Q43000321)

12 November 2017

Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application (English)

1 reference

12 November 2017

Norman M Kneteman

1

1 reference

12 November 2017

Amy J Weiner

2

1 reference

12 November 2017

John O'Connell

3

1 reference

12 November 2017

Marc Collett

4

1 reference

12 November 2017

Tiejun Gao

5

1 reference

12 November 2017

Lea Aukerman

6

1 reference

12 November 2017

Rosemary Kovelsky

7

1 reference

12 November 2017

Zhi-Jie Ni

8

1 reference

12 November 2017

Qing Zhu

9

1 reference

12 November 2017

Ahmad Hashash

10

1 reference

12 November 2017

Janine Kline

11

1 reference

12 November 2017

Belinda Hsi

12

1 reference

12 November 2017

Daniel Schiller

13

1 reference

12 November 2017

Donna Douglas

14

1 reference

12 November 2017

D Lorne J Tyrrell

15

1 reference

12 November 2017

David F Mercer

16

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

12 November 2017

1 reference

12 November 2017

43

1 reference

12 November 2017

1346-1353

1 reference

12 November 2017

6

1 reference

Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.

12 November 2017

1 reference

Hepatitis C: an update on the silent epidemic

21 January 2018

1 reference

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

7 January 2021

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002)

1 reference

7 January 2021

Hepatitis C treatment update

1 reference

7 January 2021

Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator

1 reference

7 January 2021

Hepatitis C virus replication in mice with chimeric human livers

1 reference

7 January 2021

Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase

1 reference

7 January 2021

Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell Culture

1 reference

7 January 2021

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

1 reference

7 January 2021

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

1 reference

7 January 2021

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

1 reference

7 January 2021

Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.

1 reference

7 January 2021

Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations

1 reference

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

7 January 2021

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

7 January 2021

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

7 January 2021

Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21209

1 reference

12 November 2017

1 reference